Central nervous symptoms as the prominent manifestation of Sjögren’s disease (SjD): a case report

Read full text
Authors: Naidi Wang, Yuebo Jin, Shanshan Lu, Gongming Li, Yuhui Li, Jing He
Cited by: 1
References: 21

Abstract

BACKGROUND: Sjögren's disease (SjD) is a chronic autoimmune disease featured by lymphocytic infiltration of exocrine glands and numerous organ involvements, but central nervous system involvement is relatively rare. Due to the variety of symptoms, diagnosis is particularly difficult under certain conditions, which may delay the optimal timing of treatment. Increased clinical awareness and effective pharmacotherapies are urgently needed. CASE PRESENTATION: A case of a 39-year-old female was initially considered to have an intracranial occupancy based upon rapidly progressing nervous symptoms including intermittent fever, parieto-occipital headache, numbness and weakness in the hand, blurred vision, memory impairment and imaging findings, but it was ultimately clarified that she had SjD involving nervous system, with immunological results showing positive antinuclear antibodies (1:640) and anti-SSA/SSB antibodies (+++) in serum and pathological findings suggesting vasculitis of brain. Finally, she was successfully treated with rituximab. CONCLUSIONS: The onset of SjD may even only manifest as neurological symptoms, which could be easily confused with other systemic or neurological diseases, thus demanding careful differential diagnosis through a detailed medical history and immunological, even pathological examinations to clarify the etiology. Rituximab is an effective treatment option for SjD involving nervous systems, which is an option not commonly featured in standard treatment protocols.

Fields of Study & Subjects

Salivary Gland Disorders and Functions Autoimmune Neurological Disorders and Treatments Systemic Sclerosis and Related Diseases

Publication details

Journal / source
BMC Neurology
Publisher
Springer Science and Business Media LLC
Volume
26
Issue
1
Pages
97–97
Publication date
19 January 2026
Language
EN